[go: up one dir, main page]

MX2013014614A - Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina. - Google Patents

Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina.

Info

Publication number
MX2013014614A
MX2013014614A MX2013014614A MX2013014614A MX2013014614A MX 2013014614 A MX2013014614 A MX 2013014614A MX 2013014614 A MX2013014614 A MX 2013014614A MX 2013014614 A MX2013014614 A MX 2013014614A MX 2013014614 A MX2013014614 A MX 2013014614A
Authority
MX
Mexico
Prior art keywords
signal
interference
give rise
tendency
reduce
Prior art date
Application number
MX2013014614A
Other languages
English (en)
Other versions
MX350074B (es
Inventor
Marie-Ange Buyse
Judith Baumeister
Marie-Paule Lucienne Armanda Bouche
Carlo Boutton
Veerle Snoeck
Stephanie Staelens
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47423024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013014614(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/067132 external-priority patent/WO2012042026A1/en
Priority claimed from PCT/EP2012/061304 external-priority patent/WO2012175400A1/en
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2013014614A publication Critical patent/MX2013014614A/es
Publication of MX350074B publication Critical patent/MX350074B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona, y en ciertos aspectos específicos pero no limitantes se refiere a: ensayos que se pueden usar para predecir si un ISV dado se someterá a una interferencia de proteínas como se describe en este documento y/o da origen a una señal (no específica) en tal ensayo (tal como por ejemplo en el inmunoensayo ADA). Tales ensayos predictivos se podrían usar por ejemplo para probar si un ISV dado podría tener una tendencia a dar origen a tal interferencia de proteínas y/o tal señal; para seleccionar los ISV´s que no son o son menos propensos a tal interferencia de proteínas o a dar origen a tal señal; como un ensayo o prueba que se puede usar para probar si ciertas modificaciones a un ISV reducirán (total o parcialmente) su tendencia a dar origen a tal interferencia o a tal señal; y/o como un ensayo o prueba que se puede usar para guiar la modificación o mejora de un ISV para reducir su tendencia a dar origen a tal interferencia de proteínas o señal; métodos para modificar y/o mejorar los ISV´s para remover o reducir su tendencia a dar origen a tal interferencia de proteína o a tal señal; modificaciones que se pueden introducir en un ISV que remueven o reducen su tendencia a dar origen a tal interferencia de proteínas o tal señal; los ISV´s que se han seleccionado específicamente (por ejemplo, usando ensayos descritos en este documento) para no tener una tendencia baja (más baja)/reducida para dar origen a tal interferencia de proteínas o a tal señal; los ISV´s modificadas y/o mejoradas que no tienen una tendencia o una tendencia baja(más baja)/reducida.
MX2013014614A 2011-06-23 2012-06-25 Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina. MX350074B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161500360P 2011-06-23 2011-06-23
US201161500464P 2011-06-23 2011-06-23
US201161541368P 2011-09-30 2011-09-30
PCT/EP2011/067132 WO2012042026A1 (en) 2010-09-30 2011-09-30 Biological materials related to c-met
US13/435,567 US8703135B2 (en) 2010-09-30 2012-03-30 Biological materials related to c-Met
PCT/EP2012/061304 WO2012175400A1 (en) 2011-06-23 2012-06-14 Serum albumin binding proteins
PCT/EP2012/062251 WO2012175741A2 (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Publications (2)

Publication Number Publication Date
MX2013014614A true MX2013014614A (es) 2014-08-01
MX350074B MX350074B (es) 2017-08-25

Family

ID=47423024

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013014614A MX350074B (es) 2011-06-23 2012-06-25 Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina.
MX2018007826A MX2018007826A (es) 2011-06-23 2013-12-11 Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmonoglobulina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018007826A MX2018007826A (es) 2011-06-23 2013-12-11 Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmonoglobulina.

Country Status (24)

Country Link
US (11) US20180009888A9 (es)
EP (1) EP2723769B2 (es)
JP (6) JP6258199B2 (es)
KR (7) KR102880093B1 (es)
CN (5) CN104203975B (es)
AU (7) AU2012273929B2 (es)
BR (3) BR122017005075B1 (es)
CA (3) CA3142288A1 (es)
DK (1) DK2723769T4 (es)
ES (1) ES2622006T5 (es)
FI (1) FI2974737T3 (es)
HU (1) HUE031828T2 (es)
IL (5) IL250396B (es)
IN (1) IN2014CN00373A (es)
LT (1) LT2723769T (es)
MX (2) MX350074B (es)
NZ (1) NZ780183A (es)
PH (7) PH12022550311A1 (es)
PL (1) PL2723769T5 (es)
PT (1) PT2723769T (es)
RU (1) RU2700630C2 (es)
SG (4) SG194982A1 (es)
WO (1) WO2012175741A2 (es)
ZA (1) ZA201309295B (es)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434769B1 (en) 2009-10-30 2020-11-25 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
PE20130207A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PH12022550311A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RS55775B2 (sr) 2011-06-23 2022-10-31 Ablynx Nv Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
IN2014CN00414A (es) 2011-06-23 2015-04-03 Ablynx Nv
KR102143506B1 (ko) * 2011-08-17 2020-08-12 글락소 그룹 리미티드 변형된 단백질 및 펩티드
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
AR088633A1 (es) 2011-11-04 2014-06-25 Novartis Ag Constructos extensores de vida media de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6)
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CN104781277A (zh) * 2012-09-13 2015-07-15 诺华股份有限公司 具有末端修饰的抗原结合分子
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
US11009511B2 (en) * 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US10526397B2 (en) 2015-01-21 2020-01-07 Inhibrx, Inc. Non-immunogenic single domain antibodies
IL254577B2 (en) 2015-03-31 2023-11-01 Vhsquared Ltd polypeptides
AU2016239951A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Polypeptides
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
CN107646039B (zh) 2015-04-02 2022-04-15 埃博灵克斯股份有限公司 具有有效抗hiv活性的双特异性cxcr4-cd4多肽
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
AU2016259792B2 (en) 2015-05-13 2019-07-25 Ablynx N.V. T cell recruiting polypeptides based on TCR alpha/beta reactivity
RS65904B1 (sr) 2015-05-13 2024-09-30 Ablynx Nv Polipeptidi koji regrutuju t ćelije na osnovu reaktivnosti cd3
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
RU2018119732A (ru) 2015-10-30 2019-12-03 Аблинкс Нв Полипептиды против il-23
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
EP3374395A1 (en) * 2015-11-12 2018-09-19 Ablynx NV Improved p2x7 receptor binders and polypeptides comprising the same
NO2768984T3 (es) * 2015-11-12 2018-06-09
PT3374392T (pt) * 2015-11-13 2022-02-07 Ablynx Nv Domínios variáveis de imunoglobulina que se ligam a albumina sérica melhorados
JP7046804B2 (ja) 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． 改良された血清アルブミン結合剤
WO2017087589A2 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
BR112018009972B1 (pt) 2015-11-18 2021-08-24 Merck Sharp & Dohme Corp Ligante de ctla4, ligante, recipiente ou dispositivo de injeção, polinucleotídeo, vetor, célula hospedeira, métodos para fabricar o ligante de ctla4 e para prevenir que ctla4 se ligue à cd80 ou cd86 e usos do referido ligante de ctla4
JP6779997B2 (ja) 2015-11-18 2020-11-04 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ１／ｃｔｌａ４結合性物質
KR20180080337A (ko) 2015-11-27 2018-07-11 아블린쓰 엔.브이. Ｃｄ40ｌ을 억제하는 폴리펩티드
US10597449B2 (en) 2015-12-04 2020-03-24 Boehringer Ingelheim International Gmbh Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
RU2765809C2 (ru) * 2016-06-23 2022-02-03 Аблинкс Н.В. Усовершенствованные фармакокинетические анализы для одиночных вариабельных доменов иммуноглобулина
WO2018050833A1 (en) 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
KR102665596B1 (ko) 2016-11-16 2024-05-14 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
CN117285623A (zh) 2017-01-17 2023-12-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
PL3571224T3 (pl) 2017-01-17 2025-01-07 Ablynx Nv Ulepszone środki wiążące albuminę surowicy
SG11201908154RA (en) 2017-03-31 2019-10-30 Ablynx Nv Improved immunogenicity assays
CN110637030B (zh) 2017-05-31 2024-06-11 勃林格殷格翰国际有限公司 拮抗肿瘤细胞中Wnt信号传导的多肽
US12129308B2 (en) 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins
PT3630847T (pt) 2017-06-02 2024-11-21 Merck Patent Gmbh Imunoglobulinas que se ligam a adamts
KR20250005464A (ko) 2017-06-02 2025-01-09 메르크 파텐트 게엠베하 Adamts5, mmp13 및 아그레칸 결합성 폴리펩타이드
TW202413408A (zh) 2017-06-02 2024-04-01 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
CN111108126B (zh) 2017-07-19 2024-04-26 非营利性组织佛兰芒综合大学生物技术研究所 血清白蛋白结合剂
WO2019038986A1 (ja) 2017-08-23 2019-02-28 本田技研工業株式会社 鞍乗り型車両のエアバッグ装置
CN111315784A (zh) 2017-10-31 2020-06-19 非营利性组织佛兰芒综合大学生物技术研究所 新的抗原结合嵌合蛋白及其方法和用途
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US12055551B2 (en) 2018-07-10 2024-08-06 Regeneron Pharmaceuticals, Inc. Methods for mitigating drug target interference in an anti-drug antibody (ADA) immunoassay
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
KR20220064953A (ko) 2019-06-21 2022-05-19 소리소 파마슈티컬스 인크. 폴리펩티드
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
US20220411495A1 (en) 2019-11-27 2022-12-29 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
WO2021110816A1 (en) 2019-12-06 2021-06-10 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23
PH12022551231A1 (en) 2019-12-06 2023-07-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
CN114980974A (zh) 2019-12-09 2022-08-30 艾伯霖克斯公司 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
CA3165429A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
KR20230012464A (ko) 2020-02-25 2023-01-26 브이아이비 브이지더블유 류신-풍부 반복 키나제 2 알로스테릭 조절제
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
US12509522B2 (en) 2020-09-25 2025-12-30 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-13 and OX40L
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
AU2021402183A1 (en) 2020-12-14 2023-07-06 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
WO2022129560A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
WO2022129637A1 (en) 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
EP4288095A1 (en) 2021-02-05 2023-12-13 Vib Vzw Sarbecovirus binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
WO2022175532A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
CN113173978B (zh) * 2021-04-22 2024-03-01 温州医科大学 一种对hpv16e6蛋白具有结合亲和力的多肽及其应用
US20240327525A1 (en) 2021-07-30 2024-10-03 Vib Vzw Cation-Independent Mannose-6-Phosphate Receptor Binders For Targeted Protein Degradation
CN118339179A (zh) * 2021-11-29 2024-07-12 江苏恒瑞医药股份有限公司 经修饰的蛋白或多肽
EP4448783A1 (en) 2021-12-13 2024-10-23 Heraeus Medical GmbH Tests and methods for detecting bacterial infection
EP4448574A1 (en) 2021-12-17 2024-10-23 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123
EP4463479A1 (en) 2022-01-12 2024-11-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
TW202342521A (zh) 2022-02-23 2023-11-01 日商武田藥品工業股份有限公司 條件性雙特異性結合蛋白
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
CA3249283A1 (en) 2022-05-18 2023-11-23 Vib Vzw BINDERS OF SARBECOVIRUS SPICULE S2 SUBUNITS
JP2025523403A (ja) 2022-06-08 2025-07-23 タイダル・セラビューティクス・インコーポレイテッド イオン化可能なカチオン性脂質及び脂質ナノ粒子、並びにその合成方法及び使用
AR129614A1 (es) 2022-06-14 2024-09-11 Ablynx Nv Dominios variables únicos de inmunoglobulina que se dirigen al receptor de células t
CA3263005A1 (en) 2022-07-27 2024-02-01 Sanofi POLYPEPTIDES BINDING TO A SPECIFIC EPITOPE OF THE NEONATAL FC RECEPTOR
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate
WO2024137731A2 (en) 2022-12-21 2024-06-27 Genzyme Corporation Anti‑pd‑1×4‑1bb binding proteins
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
EP4648792A2 (en) 2023-01-09 2025-11-19 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
CN121013866A (zh) 2023-02-10 2025-11-25 阿穆尼克斯制药公司 靶向前列腺特异性膜抗原（psma）的组合物及其制备和使用方法
AU2024221136A1 (en) 2023-02-17 2025-10-02 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
WO2024192065A1 (en) 2023-03-14 2024-09-19 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
AU2024267410A1 (en) 2023-05-08 2026-01-08 Sanofi Glycosylation of immunoglobulin single variable domains
TW202448951A (zh) 2023-05-17 2024-12-16 美商奧迪希治療公司 經修飾之單域抗體
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
AU2024308381A1 (en) 2023-06-29 2025-11-20 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
AR134267A1 (es) 2023-11-08 2025-12-17 Sanofi Sa Degradador lisosómico basado en cd25 y usos del mismo
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025262150A2 (en) 2024-06-18 2025-12-26 Ablynx Nv Antibody-recruiting molecules
WO2025265116A1 (en) 2024-06-21 2025-12-26 Georgia State University Research Foundation, Inc. Nanobodies to henipavirus and uses thereof
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026006708A2 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use
WO2026024863A2 (en) 2024-07-24 2026-01-29 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
ES2103770T3 (es) 1990-11-26 1997-10-01 Akzo Nobel Nv Procedimiento de produccion de anticuerpos monoclonales.
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7622259B1 (en) 1999-07-05 2009-11-24 K.U. Leuven Research & Development Detection of von-Willebrand factor (vWF) activity
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US20020155574A1 (en) 2000-08-01 2002-10-24 Novozymes A/S Alpha-amylase mutants with altered properties
AU2001289930A1 (en) 2000-09-25 2002-04-08 Rega Stichting Vzw Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
ES2368623T3 (es) 2000-12-13 2011-11-18 Bac Ip B.V. Matrices de proteína de dominios variables de inmunoglobulina de cadena pesada de camilidae.
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
EP2258392A1 (en) 2002-11-08 2010-12-08 Ablynx N.V. Method of administering therapeutic polypeptides
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
CA2510003A1 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
KR20070117002A (ko) 2003-11-04 2007-12-11 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 고지혈증·고알부민혈증 모델 동물
RU2398777C2 (ru) 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
EP1863847A2 (en) 2004-12-02 2007-12-12 Domantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
HUE039846T2 (hu) * 2005-05-20 2019-02-28 Ablynx Nv Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2006129843A2 (en) † 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
BRPI0619224A2 (pt) 2005-12-01 2017-06-20 Domantis Ltd monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
JP2009519011A (ja) 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
EP1976991A1 (en) * 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
TW200815470A (en) 2006-03-30 2008-04-01 Novartis Ag Compositions and methods of use for antibodies of c-Met
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CN101646689A (zh) * 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
ATE536369T1 (de) 2006-10-11 2011-12-15 Ablynx Nv Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
CA2671581A1 (en) * 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
AU2007332855B2 (en) 2006-12-08 2012-08-16 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against ANGPTL3
EP2102241A2 (en) 2006-12-15 2009-09-23 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
US8906680B2 (en) * 2006-12-22 2014-12-09 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
CN104231082B (zh) * 2007-05-24 2018-12-21 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AR062123A1 (es) * 2007-07-27 2008-10-15 Inst Nac De Tecnologia Agropec Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
WO2009042589A1 (en) * 2007-09-24 2009-04-02 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
CA2704745C (en) 2007-11-05 2019-01-15 Danisco Us Inc. Alpha-amylase variants with altered properties
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
JP5715420B2 (ja) * 2007-12-28 2015-05-07 ジェネンテック， インコーポレイテッド 抗ヘッジホッグ抗体
BRPI0907648B1 (pt) 2008-01-29 2022-01-11 Institute Of Molecular Biology And Genetics National Academy Of Science Of Ukraine Anticorpo isolado humanizado, usos de um anticorpo, métodos para preparar um anticorpo, para gerar anticorpos imunorreativos com slc34a2 e para triar ou identificar agentes ou compostos que modulam slc34a2, composições, ácido nucleico isolado, e, microorganismo hospedeiro
CA2721202A1 (en) * 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
CN102099378B (zh) 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
US7858729B2 (en) 2008-05-29 2010-12-28 Novomer, Inc. Methods of controlling molecular weight distribution of polymers and compositions thereof
WO2009147248A2 (en) 2008-06-05 2009-12-10 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20110200525A1 (en) * 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
US8372808B2 (en) 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
WO2010100135A1 (en) † 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EA021146B1 (ru) 2009-03-27 2015-04-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств
MX2011010681A (es) 2009-04-10 2012-01-20 Ablynx Nv Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
US8450888B2 (en) 2009-04-20 2013-05-28 General Electric Company Integrated brushless starter/generator system
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
EP2451839B1 (en) * 2009-07-10 2020-04-22 Ablynx N.V. Method for the production of variable domains
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
US9644022B2 (en) * 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3309176B1 (en) * 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
CA2784498A1 (en) * 2009-12-18 2011-06-23 Sanofi Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
KR101721187B1 (ko) 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
FI3904391T3 (fi) 2010-03-10 2024-10-02 Genmab As Monoklonaaliset vasta-aineet c-Met:iä vastaan
US8937164B2 (en) * 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
CN102971341A (zh) 2010-04-30 2013-03-13 埃博灵克斯股份有限公司 针对异二聚体细胞因子IL-23的p19亚基的纳米抗体的氨基酸序列
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
CN103443126B (zh) * 2011-01-06 2016-11-23 葛兰素集团有限公司 结合TGFβ受体II的配体
AU2012237287B2 (en) 2011-03-30 2016-09-08 Ablynx Nv Methods of treating immune disorders with single domain antibodies against TNF-alpha
WO2012130314A1 (en) † 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
IN2014CN00414A (es) 2011-06-23 2015-04-03 Ablynx Nv
PH12022550311A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US20150344568A1 (en) 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
MX2014001019A (es) 2011-07-27 2014-05-13 Glaxo Group Ltd Dominios variables singulares anti-vgf fusionados con dominios de fc.
KR102143506B1 (ko) * 2011-08-17 2020-08-12 글락소 그룹 리미티드 변형된 단백질 및 펩티드
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US8614548B2 (en) 2012-01-19 2013-12-24 Sonoco Development Incorporated Electroluminescent display and method for production
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20130316143A1 (en) 2012-05-22 2013-11-28 Owens Corning Intellectual Capital, Llc Laminated foam product and methods for making laminated foam products
WO2014111550A1 (en) † 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
AU2015334984A1 (en) 2014-10-21 2017-04-13 Ablynx Nv Treatment of IL-6R related diseases
NO2768984T3 (es) 2015-11-12 2018-06-09
PT3374392T (pt) 2015-11-13 2022-02-07 Ablynx Nv Domínios variáveis de imunoglobulina que se ligam a albumina sérica melhorados
WO2017087589A2 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
BR112018009972B1 (pt) 2015-11-18 2021-08-24 Merck Sharp & Dohme Corp Ligante de ctla4, ligante, recipiente ou dispositivo de injeção, polinucleotídeo, vetor, célula hospedeira, métodos para fabricar o ligante de ctla4 e para prevenir que ctla4 se ligue à cd80 ou cd86 e usos do referido ligante de ctla4
JP6779997B2 (ja) 2015-11-18 2020-11-04 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ１／ｃｔｌａ４結合性物質
JP7046804B2 (ja) 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． 改良された血清アルブミン結合剤
US10626186B2 (en) 2016-01-26 2020-04-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-VWF D'D3 single-domain antibodies and methods of use
IL310340A (en) * 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
CN117285623A (zh) * 2017-01-17 2023-12-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
KR20250005464A (ko) * 2017-06-02 2025-01-09 메르크 파텐트 게엠베하 Adamts5, mmp13 및 아그레칸 결합성 폴리펩타이드
TW202413408A (zh) 2017-06-02 2024-04-01 比利時商艾伯林克斯公司 結合聚集蛋白聚糖之免疫球蛋白
PT3630847T (pt) * 2017-06-02 2024-11-21 Merck Patent Gmbh Imunoglobulinas que se ligam a adamts
US12129308B2 (en) * 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins
CA3089211A1 (en) * 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
WO2022129560A1 (en) * 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor

Also Published As

Publication number Publication date
JP6258199B2 (ja) 2018-01-10
MX350074B (es) 2017-08-25
AU2019201606B2 (en) 2021-04-01
KR20180086280A (ko) 2018-07-30
SG10201707604SA (en) 2017-11-29
HUE031828T2 (en) 2017-08-28
JP6982400B2 (ja) 2021-12-17
PH12022550312A1 (en) 2023-01-23
PH12017501178A1 (en) 2018-07-23
US20170275360A1 (en) 2017-09-28
CA3142288A1 (en) 2012-12-27
PH12013502669A1 (en) 2014-02-10
EP2723769B1 (en) 2017-01-11
SG10201605048XA (en) 2016-07-28
IL250396A0 (en) 2017-03-30
US20210403536A1 (en) 2021-12-30
US20220298227A9 (en) 2022-09-22
CN108663504B (zh) 2021-06-22
JP2018162305A (ja) 2018-10-18
PL2723769T5 (pl) 2022-10-17
PH12022550310A1 (en) 2023-01-23
US20210388062A1 (en) 2021-12-16
CN108659120A (zh) 2018-10-16
KR102880093B1 (ko) 2025-10-31
CN108663504A (zh) 2018-10-16
RU2014102007A (ru) 2015-11-27
PH12022550313A1 (en) 2023-01-23
AU2024200309A1 (en) 2024-02-08
AU2019201606A1 (en) 2019-04-04
JP6869923B2 (ja) 2021-05-12
BR122017005075A2 (pt) 2019-09-03
LT2723769T (lt) 2017-04-10
IL229503B (en) 2022-06-01
IL293155B1 (en) 2026-01-01
KR102240318B1 (ko) 2021-04-15
AU2012273929B2 (en) 2017-04-27
AU2017204339B2 (en) 2019-03-28
AU2021201506B2 (en) 2023-10-19
BR112013032145A8 (pt) 2018-07-03
CN108659121A (zh) 2018-10-16
MX2018007826A (es) 2021-12-08
US20180355031A1 (en) 2018-12-13
WO2012175741A3 (en) 2013-02-14
IL229503A0 (en) 2014-01-30
US20200216532A1 (en) 2020-07-09
KR20240033183A (ko) 2024-03-12
RU2700630C2 (ru) 2019-09-18
BR122017005075B1 (pt) 2022-09-20
PT2723769T (pt) 2017-04-04
ES2622006T3 (es) 2017-07-05
KR101965462B1 (ko) 2019-04-04
CN104203975B (zh) 2018-05-11
JP2014520134A (ja) 2014-08-21
IL250396B (en) 2022-06-01
AU2021201506A1 (en) 2021-03-25
IN2014CN00373A (es) 2015-04-03
BR112013032145B1 (pt) 2022-09-20
US20170275361A1 (en) 2017-09-28
US20220119497A1 (en) 2022-04-21
KR20190107200A (ko) 2019-09-18
KR20220114104A (ko) 2022-08-17
PL2723769T3 (pl) 2017-07-31
WO2012175741A2 (en) 2012-12-27
PH12013502669B1 (en) 2018-08-10
BR122018012485B1 (pt) 2022-09-20
IL324872A (en) 2026-01-01
IL293163A (en) 2022-07-01
DK2723769T3 (en) 2017-04-03
KR20190041513A (ko) 2019-04-22
JP2017160230A (ja) 2017-09-14
CN104203975A (zh) 2014-12-10
US11192938B2 (en) 2021-12-07
US12516105B2 (en) 2026-01-06
AU2018202782B2 (en) 2020-07-16
AU2020230299B2 (en) 2022-10-06
NZ617995A (en) 2016-06-24
US10858418B2 (en) 2020-12-08
US12006352B2 (en) 2024-06-11
EP2723769B2 (en) 2022-06-15
AU2020230299A1 (en) 2020-10-01
US20210388061A1 (en) 2021-12-16
NZ716279A (en) 2017-07-28
CA2837998A1 (en) 2012-12-27
RU2019128430A (ru) 2019-10-25
DK2723769T4 (da) 2022-09-05
US11192937B2 (en) 2021-12-07
SG194982A1 (en) 2013-12-30
JP2024050769A (ja) 2024-04-10
EP2723769A2 (en) 2014-04-30
US20140199295A1 (en) 2014-07-17
CN108653728B (zh) 2022-11-18
KR102246924B1 (ko) 2021-04-30
IL293155A (en) 2022-07-01
JP2021107426A (ja) 2021-07-29
KR102430693B1 (ko) 2022-08-08
CN108653728A (zh) 2018-10-16
KR20210047369A (ko) 2021-04-29
AU2017204339A1 (en) 2017-07-13
BR112013032145A2 (pt) 2017-12-05
US20230242620A1 (en) 2023-08-03
FI2974737T3 (fi) 2026-01-22
KR102025035B1 (ko) 2019-11-04
PH12022550309A1 (en) 2023-01-23
ZA201309295B (en) 2015-01-28
SG10201805064SA (en) 2018-07-30
JP2022031790A (ja) 2022-02-22
KR20140040779A (ko) 2014-04-03
US20180009888A9 (en) 2018-01-11
CA3141978A1 (en) 2012-12-27
NZ780183A (en) 2024-12-20
PH12022550311A1 (en) 2023-01-23
US20200325221A1 (en) 2020-10-15
ES2622006T5 (es) 2022-10-13
CA2837998C (en) 2022-03-01
AU2018202782A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
MX2013014614A (es) Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina.
MX2015012823A (es) Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo.
WO2013074676A3 (en) Assays for selecting a treatment regimen for a subject with depression and methods for treatment
CL2016001256A1 (es) Composiciones y métodos para anticuerpos dirigidos factor de p (divisional de sol. n° 1640-14).
BR112015014833A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno deste, ácido nucléico isolado, célula hospedeira, método de ensaiar uma amostra de tecido removido de um humano para expressão de pd-l1, estojo, e, composição de anticorpo que compreende uma mistura de moléculas do anticorpo
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
MX2012009168A (es) Raton de cadena ligera comun.
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
MX2019007958A (es) Biblioteca de moleculas de union dependientes de la concentracion ionica.
WO2013096822A3 (en) Test device for optical and electrochemical assays
BR112014021081A2 (pt) anticorpos para a metaloproteinase da matriz 9
MX357623B (es) Ratones de cadena ligera universal humanizados.
BR112012011230A2 (pt) fatores de risco e previsão de infarto do miocárdio
IN2014DN08064A (es)
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
BR112013001398A2 (pt) método, reagente e kit para medir hemoglobina glicada
EA201690465A1 (ru) Способ оценки эффектов композиции, содержащей микроорганизмы, на кишечную микробиоту
BR112016010510A2 (pt) método, arranjo e uso do mesmo
MX386714B (es) Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
IN2014DN08063A (es)
BRPI0803089A2 (pt) ensaio de proteìnas
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
BR112012023671A2 (pt) Agentes fluorescentes arsênicos e ensaios
EP4350345A3 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
RU2010140410A (ru) Применение смесей, имитирующих цельную кровь и диагностические сыворотки, для обучения студентов методике определения групп крови по системе ав0

Legal Events

Date Code Title Description
FG Grant or registration